マサチューセッツ州におけるリンパ腫の臨床試験
マサチューセッツ州内の拠点で、リンパ腫に関する33件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト（英語）
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Beth Israel Deaconess Medical Center - Research, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07192471A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07015242A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
- Mass General Hospital, Boston
被験者募集中
18歳以上 · 全性別 · 2026/09/28更新 · NCT07013435Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
- Mass General Brigham, Boston
被験者募集中
18歳以上 · 全性別 · 2026/09/28更新 · NCT07014293A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Dana Farber Cancer Institute., Boston
被験者募集中第1/2相
25歳以下 · 全性別 · 2026/09/25更新 · NCT04094610Epco, Zanu, Ritux for R/R FL or MZL
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06563596AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Boston
- Research Site, Boston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/14更新 · NCT06137144CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
12 Months – 21 Years · 全性別 · 2026/09/11更新 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Boston
被験者募集中第3相
18歳〜18歳 · 全性別 · 2026/09/08更新 · NCT07509151Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04104776Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第4相
18歳以上 · 全性別 · 2026/08/11更新 · NCT07426484The CARDIOPROTECT Trial
- Beth Israel Deaconess Medical Center, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/27更新 · NCT07654426DALY II USA/ MB-CART2019.1 for DLBCL
- Dana Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0026), Boston
被験者募集中第1/2相
6 Months – 17 Years · 全性別 · 2026/07/06更新 · NCT02332668A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/17更新 · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Dana-Farber Cancer Institute, Boston
被験者募集中観察研究
全年齢 · 全性別 · 2026/05/18更新 · NCT01790152Remote Monitoring and Symptom Management Digital Application
- Massachusetts General Hospital, Boston
被験者募集中
18歳以上 · 全性別 · 2026/04/28更新 · NCT07553572Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
被験者募集中
18歳以上 · 全性別 · 2026/04/21更新 · NCT05646576CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT03328078Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
- Dana Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/04/13更新 · NCT06923397A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳〜66歳 · 全性別 · 2026/03/17更新 · NCT06859424Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
- Beth Israel Deaconess Medical Center, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/13更新 · NCT06510309Odronextamab in Low Tumor Volume Advanced FL
- Beth Israel Deaconess Medical Center, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/13更新 · NCT07128641Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
- Beth Israel Deaconess Medical Center, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/13更新 · NCT06510361A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/05更新 · NCT05800366BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/20更新 · NCT06854003Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/20更新 · NCT06475235CONFIRM: Magnetic Resonance Guided Radiation Therapy
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/02/09更新 · NCT04368702Avo In R/R And Previously Untreated MCL
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/21更新 · NCT04855695Mosunetuzumab for CLL MRD Clearance
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/12/15更新 · NCT07052695A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
- Dana Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2025/12/05更新 · NCT06986174HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2025/09/17更新 · NCT06487247ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。